Sakar Healthcare profit more than doubled to Rs 11.30 crore on a consolidated basis in the September 2026 quarter, compared with Rs 4.54 crore a year earlier. Revenue from operations rose 51.9% to Rs 87.41 crore, with the company attributing growth partly to its oncology business.

Sakar Healthcare profit outpaces revenue growth

Revenue from operations increased from Rs 57.56 crore in the corresponding quarter a year earlier. Net profit grew faster than sales, with management citing a better oncology product mix, operating leverage and disciplined cost management among the factors supporting second-quarter performance.

The company also pointed to new oncology approvals and strong demand across geographies. These are management’s explanations for the improvement; the available figures do not isolate the contribution of each factor.

Oncology approvals and market access support expansion

Managing Director Sanjay Shah described the quarter as a period of meaningful progress for the oncology business, highlighting regulatory approvals, technology transfers and global market access.

For background, the company’s oncology regulatory announcements list EU GMP approval for its anti-cancer unit and WHO GMP approval for its oncology injection unit. Those historical disclosures provide context for the business, rather than verification of the September 2026 earnings or the timing of the latest approvals.

Read More News

More FinanceVelix news

Disclaimer

This FinanceVelix article provides general information, not personalized financial, investment, legal, or tax advice. Market prices, interest rates and economic conditions can change; investments carry a risk of loss. Facts reflect the material available when published and may change. Check important information independently and consult a qualified professional when needed. Mentioning an asset, company, or service is not an endorsement.